Mesa Labs sets fiscal 2027 revenue target of $250m-$255m after modest quarterly growth

Mesa Laboratories expects revenue of $250 million to $255 million in fiscal 2027, along with adjusted EBITDA of $66 million to $68 million. These are the first full-year targets the company has given for the year, and it published them alongside second-quarter results.

Revenue for the quarter to 30 September 2026 was $62.3 million, up 2.6% on the same period a year earlier. The company reported sharply higher operating and net income and a lower leverage ratio. The announcement summary we reviewed gives no absolute profit or debt figures, so the scale of those improvements cannot be assessed here.

Mesa also described a savings and restructuring programme that began in October. The available information does not say what the plan involves, what it will cost or how much it is meant to save, so its contribution to the EBITDA outlook is unclear.

On the regulatory side, the company said the FDA inspected its Bozeman, Montana, biological indicator site in September and issued no Form 483. Investigators use that form at the end of an inspection to list conditions that may breach US food and drug law (context, not from the company). The summary does not say how broad the inspection was or which products it covered.